Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Ferring signs licensing agreement with Seikagaku for condoliase

Aug. 29, 2016

Researchers from Genentech identify novel potent and selective NIK inhibitors

Aug. 26, 2016

Hemispherx Biopharma's NDA for rintatolimod receives approval in Argentina

Aug. 24, 2016

Novel compound E-6887 shows promise for treating lupus

Aug. 24, 2016

Gilead begins phase III program for filgotinib in rheumatoid arthritis

Aug. 23, 2016

Medshine Discovery discloses JAK inhibitors

Aug. 12, 2016

MPC-300-IV shows dose-related improvements in phase II trial in biologic refractory RA

Aug. 11, 2016

Ablynx reports topline phase IIb results for vobarilizumab in patients with rheumatoid arthritis

Aug. 10, 2016

Autologous BMC is safe and effective in treating patients with atrophic non-unions

Aug. 8, 2016

Omeros' lead MASP-3 inhibitor shows efficacy in arthritis model

Aug. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...